Alexandra Kuznetsova
Leo Pharma (Denmark)(DK)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Food Allergy and Anaphylaxis Research, Pancreatic function and diabetes, Ubiquitin and proteasome pathways, Diabetes and associated disorders
Most-Cited Works
- → Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*(2020)563 cited
- → IRS2 Signaling in LepR-b Neurons Suppresses FoxO1 to Control Energy Balance Independently of Leptin Action(2012)61 cited
- → Insulin Receptor Substrate-2 in β-Cells Decreases Diabetes in Nonobese Diabetic Mice(2009)21 cited
- → Trimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in mice(2016)9 cited
- → Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.(2019)3 cited
- → Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2(2021)2 cited
- → Abstract 3195: DYRK1B inhibitors prevent pharmacologic quiescence and sensitize lung cancers to EGFR inhibitors(2017)1 cited
- → Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis(2020)1 cited
- → Abstract 3038: Implication of DYRK1B Kinase in ovarian cancers and utilization of DYRK1B Inhibitors as a novel therapeutic strategy for ovarian cancer(2019)1 cited
- → Abstract 5161: Validation of drug candidates targeting dormant cancers in live cells as a key for successful translation into the clinic(2020)